AstraZeneca, the British pharmaceutical company widely known for its COVID-19 vaccine, and U.S. Bristol-Myers Squibb (BMS) are engaged in discussions over a potential USD 400B merger, according to reports. If completed, the proposed merger would create the world’s fourth-largest pharmaceutical company with an enterprise value of approximately 400 billion dollars. Such a transaction would also rank as the largest deal ever completed in the pharmaceutical and biotech industries.
AstraZeneca currently has a market capitalization of approximately 196 billion pounds (approximately 377 trillion Korean won), making it the second-largest listed company on the UK stock market after HSBC, while BMS has a market capitalization of approximately 133 billion dollars (approximately 190 trillion Korean won). Reports indicate that both companies have been holding merger discussions over recent months. Although negotiations could result in an agreement in the near future, there is also the possibility that talks may be delayed or ultimately fail. The structure of the proposed transaction has yet to be finalized, though a combination of cash and stock payments is regarded as the most likely approach for the USD 400B merger.
Combined Cancer Portfolio Would Strengthen Global Market Position
Both AstraZeneca and BMS have built their growth strategies around anticancer drugs, making oncology a central focus of the proposed combination. AstraZeneca’s portfolio includes lung cancer treatment ‘Tagrisso’, breast cancer treatment ‘Enhertu’, and immune-oncology drug ‘Imfinzi’, among others. BMS markets immune-oncology drugs ‘Opdivo’ and ‘Yervoy’, among others. If the companies proceed with the USD 400B merger, the combined business would hold a dominant market share and an extensive pipeline of new drug candidates in the global anticancer drug market.
AstraZeneca was previously the target of a takeover attempt by U.S. Pfizer in 2014, when Pfizer proposed an acquisition valuing the company at approximately 70 billion pounds. AstraZeneca rejected that offer and has since experienced rapid growth driven by its anticancer medicines, reaching an enterprise value approaching 200 billion pounds. Last year, AstraZeneca generated global sales of 58.7 billion dollars and is targeting annual sales of 80 billion dollars by 2030. Nearly half of its current total sales originate from the U.S., the world’s largest pharmaceutical market, and a merger with BMS would further reinforce its business presence there. Meanwhile, BMS continues to face medium- to long-term sales declines resulting from patent expirations of key medications. Although it acquired biotech company Celgene for 74 billion dollars in 2019, the anticipated benefits have not been fully realized, leaving the company seeking new growth drivers and an expanded pipeline of new drugs.
Competition Authorities Expected to Closely Scrutinize Proposed Deal
The most significant challenge facing the proposed USD 400B merger is expected to come from antitrust reviews by competition authorities across multiple countries. Regulatory concerns are likely because the two companies have substantial overlap in their anticancer drug businesses. In particular, BMS’s Opdivo and AstraZeneca’s Imfinzi directly compete in the treatment of non-small cell lung cancer. As a result, competition authorities are expected to closely examine whether combining the two pharmaceutical companies could reduce competition within specific therapeutic markets before any merger is allowed to proceed.
